These stocks aren't overvalued the way much of the market is today.
News & Analysis: GlaxoSmithKline
GSK's stock performed better in 2019, but will it remain that way in 2020?
These promising stocks have been flying under the radar this year, but they're worth another look.
One overseas income stock has what looks to be a sustainable payout of nearly 10%
AbbVie and GlaxoSmithKline are both poised for a big 2020. Still, one stock is clearly the better buy right now.
GSK earnings call for the period ending September 30, 2019.
Which stock is the better pick between these two healthcare giants?
Investors have lost faith in the biopharma, which is sitting at its lowest market cap in two years. But Wall Street may be overlooking a significant catalyst from a partnered asset.
Which pharmaceutical stock could provide investors with the best possible return?
Is the debt-laden British pharmaceutical giant a good investment now?